StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Upfront & milestone payments received for out-licensed by Quarter

Upfront & milestone payments received for out-licensed products — Worldwide ($M) ($M)

QuarterlyAnnual

Merck Upfront & milestone payments received for out-licensed: $0M in Q2 2026, down 100.0% from a year earlier. That is the lowest of the 14 quarters on record here.

Latest, Q2 2026
0
Period ended Jun 30, 2026
Change on a year earlier
-100.0%
5 in Q2 2025
History
14 quarters
Since Q1 2022
Sources
4
Documents cited below

Where the Q2 2026 figure comes from

“$132 million and $0 million in the first and second quarter of 2026”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 Footnote (Upfront and milestone payments received for out-licensed products).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedUpfront & milestone payments received for out-licensed products — Worldwide ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20260-100.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026132+38.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202527+80.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202511-26.7%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2025Jun 30, 20255-66.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202595+55.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 202415–Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202415–Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 202415+400.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202461+19.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2023Jun 30, 20233-90.6%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 202351-55.3%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q2 2022Jun 30, 202232–Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2022Mar 31, 2022114–Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗

Cite this data

StockData. (2026). Merck Upfront & milestone payments received for out-licensed ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-outlicensed-milestones

See every metric in the Merck KPI table. Data updated Oct 26, 2026.